Scalper1 News
For the past year, the talk concerning Bristol-Myers Squibb has focused on its cancer drugs. This is understandable, since Bristol-Myers’ (BMY) recently launched Opdivo is projected to take in nearly $9 billion a year by 2020, and looks like it will carry other immuno-oncology drugs such as Yervoy to greater sales as well. At the same time, Bristol-Myers has scaled back its ambitions in virology as Gilead Sciences (GILD) has taken the lead in the Scalper1 News
Scalper1 News